Literature DB >> 32097752

Associations of C-reactive protein and fibrinogen with mortality from all-causes, cardiovascular disease and cancer among U.S. adults.

Junxiu Liu1, Yanan Zhang2, Carl J Lavie3, Fred K Tabung4, Jiting Xu5, Qingwei Hu6, Lixia He7, Yunxiang Zhang8.   

Abstract

C-reactive protein (CRP) and fibrinogen are associated with an increased risk of death with suggested differences by gender, diet quality and race/ethnicity. However, the current evidence is limited. We used data including 8646 men and 9880 women from the National Health and Nutrition Examination Survey (NHANES) Linked Morality cohort (1999-2011) to investigate the associations of CRP and fibrinogen with mortality overall and by gender, race/ethnicity and diet quality. Cox-proportional hazard model was used to quantify the associations. With a median follow-up of 6 years, a strong dose-response relationship was observed between CRP levels and mortality risk in men after multivariable adjustment. For subjects who survived the first two years, the adjusted hazard ratios (HRs) for total mortality across quartiles (from lower to higher) of CRP were 1.97 (95% CI: 0.62-6.33), 1.89 (0.59, 6.06) and 6.34 (2.28-17.7) (P for trend <0.001). For cardiovascular disease (CVD) mortality, its association with CRP varied by diet quality. For cancer mortality, its association differed by history of cancer, and positive associations were observed only among subjects with history of cancer. In contrast, no such association of CRP with mortality was found in women. For fibrinogen, we observed its positive association with total mortality and the HRs across quartiles of fibrinogen (from lower to higher) were 1.21 (0.88, 1.67), 1.49 (1.22, 1.82) and 1.99 (1.56, 2.55). The association with CVD mortality differed by diet quality whereas no association was found with cancer mortality. Our findings suggest that higher levels of CRP and fibrinogen were associated with lower survival from total and CVD; the associations of CRP with mortality were more pronounced in men than women. Diet quality is an effect modifier for the association of CRP and fibrinogen with CVD mortality.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  C-reactive protein; Cancer; Cardiovascular disease; Diet quality; Fibrinogen; Mortality

Mesh:

Substances:

Year:  2020        PMID: 32097752     DOI: 10.1016/j.ypmed.2020.106044

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  6 in total

1.  High-sensitivity C-reactive protein and all-cause mortality in four diverse populations: The CRONICAS Cohort Study.

Authors:  Antonio Bernabe-Ortiz; Rodrigo M Carrillo-Larco; Robert H Gilman; Liam Smeeth; William Checkley; J Jaime Miranda
Journal:  Ann Epidemiol       Date:  2021-12-16       Impact factor: 3.797

2.  Association Between Neutrophil-Lymphocyte Ratio and All-Cause Mortality and Cause-Specific Mortality in US Adults, 1999-2014.

Authors:  Yang Chen; Wei Wang; Lizhong Zeng; Ke Mi; Na Li; Jie Shi; Shuanying Yang
Journal:  Int J Gen Med       Date:  2021-12-22

Review 3.  Thrombolytic Enzymes of Microbial Origin: A Review.

Authors:  Deepti Diwan; Zeba Usmani; Minaxi Sharma; James W Nelson; Vijay Kumar Thakur; Graham Christie; Gustavo Molina; Vijai Kumar Gupta
Journal:  Int J Mol Sci       Date:  2021-09-28       Impact factor: 6.208

4.  Association of Serum 25(OH)D, Cadmium, CRP With All-Cause, Cause-Specific Mortality: A Prospective Cohort Study.

Authors:  Yan Liu; Donghui Yang; Fang Shi; Fang Wang; Xiaoxue Liu; Haoyu Wen; Sumaira Mubarik; Chuanhua Yu
Journal:  Front Nutr       Date:  2022-04-27

Review 5.  Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy.

Authors:  Farwa Altaf; Shourong Wu; Vivi Kasim
Journal:  Front Mol Biosci       Date:  2021-05-28

6.  Income, inflammation and cancer mortality: a study of U.S. National Health and Nutrition Examination Survey mortality follow-up cohorts.

Authors:  Joshua E Chan; Amandeep K Mann; Daniel S Kapp; David H Rehkopf
Journal:  BMC Public Health       Date:  2020-11-26       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.